Sentinel node biopsy: Implications for adjuvant therapy | 55 min | RACGP and ACRRM Accredited
Sentinel Node Biopsy | OverviewManagement of Stage III melanoma has evolved in recent years. With the advent of effective adjuvant therapy in treating Stage III melanoma, sentinel node biopsy (SNB) is essential for accurate clinical decision-making for clinicians. In this webinar, Surgical Oncologist Prof Andrew Spillane presents on the role of SNB, the current practice undertaken at Melanoma Institute Australia and the implications for adjuvant therapy.
CLICK HERE for Additional audience questions and answers
Prof Andrew Spillane
Surgical Oncologist, Melanoma Institute Australia | Professor of Surgical Oncology, The University of Sydney
This activity has been RACGP Accredited for 2 Category 2 point
ACRRM: This online CME event is an Accredited Distance/Remote based education module as defined by the Professional Development Program of the Australian College of Rural and Remote Medicine. ACRRM member participation and information will be noted and sent directly to the ACRRM for accreditation processing. Please allow 30 days for ACRRM to send you your points. This activity is approved for 2 Core Points.
1. Describe what is sentinel lymph node biopsy (SNB)
2. Describe the benefit of SNB for melanoma patients
3. Develop a systemic approach to SNB based on latest evidence and new upcoming adjuvant treatment options for clinically occult Stage III melanoma patients.